QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$301.75
-1.07 (-0.35 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$300.29
Now: $301.75
$309.25
50-Day Range
$252.41
MA: $279.55
$307.73
52-Week Range
$155.17
Now: $301.75
$316.87
Volume168,889 shs
Average Volume210,540 shs
Market Capitalization$11.65 billion
P/E Ratio52.12
Dividend Yield0.42%
Beta0.98
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More
Bio-Techne logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854
Employees2,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.69 million
Cash Flow$7.01 per share
Book Value$36.13 per share

Profitability

Net Income$229.30 million

Miscellaneous

Market Cap$11.65 billion
Next Earnings Date2/2/2021 (Estimated)
OptionableOptionable
$301.75
-1.07 (-0.35 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

How has Bio-Techne's stock price been impacted by COVID-19 (Coronavirus)?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TECH stock has increased by 67.1% and is now trading at $301.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Bio-Techne?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Bio-Techne
.

What stocks does MarketBeat like better than Bio-Techne?

Wall Street analysts have given Bio-Techne a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Bio-Techne
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.10 by $0.33. The biotechnology company earned $204.20 million during the quarter, compared to the consensus estimate of $185.04 million. Bio-Techne had a return on equity of 11.94% and a net margin of 31.04%. The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.06 earnings per share.
View Bio-Techne's earnings history
.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Friday, November 6th. Shareholders of record on Monday, November 16th will be paid a dividend of $0.32 per share on Friday, November 27th. This represents a $1.28 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, November 13th.
View Bio-Techne's dividend history
.

What price target have analysts set for TECH?

11 brokerages have issued 12-month price objectives for Bio-Techne's stock. Their forecasts range from $220.00 to $365.00. On average, they expect Bio-Techne's share price to reach $297.60 in the next year. This suggests that the stock has a possible downside of 1.4%.
View analysts' price targets for Bio-Techne
.

Who are some of Bio-Techne's key competitors?

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 60, Pay $2.86M)
  • Mr. James T. Hippel, Exec. VP of Fin. & CFO (Age 49, Pay $1.15M)
  • Ms. Brenda S. Furlow, Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 62, Pay $821.24k)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 59, Pay $1.08M)
  • Mr. Kim Kelderman, Pres of Diagnostics & Genomics (Age 53, Pay $972.4k)
  • David Clair, Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros, VP of Sales and Marketing
  • Mr. Struan Robertson, VP of HR
  • Mr. Robert M. Gavin, Sr. VP of Analytical Solutions Division (Age 52)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Reagents Division (Age 54)

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.12%), Neuberger Berman Group LLC (3.36%), Jackson Square Partners LLC (2.56%), Champlain Investment Partners LLC (2.41%), Massachusetts Financial Services Co. MA (2.29%) and State Street Corp (2.29%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

Which major investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State Street Corp, BlackRock Inc., The Manufacturers Life Insurance Company, Neuberger Berman Group LLC, Cambridge Investment Research Advisors Inc., Sei Investments Co., and Jackson Square Partners LLC. Company insiders that have sold Bio-Techne company stock in the last year include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, Norman David Eansor, Robert V Baumgartner, and Roeland Nusse.
View insider buying and selling activity for Bio-Techne
.

Which major investors are buying Bio-Techne stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Great West Life Assurance Co. Can, Pembroke Management LTD, BP PLC, Arrowstreet Capital Limited Partnership, Massachusetts Financial Services Co. MA, Bradley Foster & Sargent Inc. CT, and Champlain Investment Partners LLC. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne
.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $301.75.

How big of a company is Bio-Techne?

Bio-Techne has a market capitalization of $11.65 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis. Bio-Techne employs 2,300 workers across the globe.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.